Systematic review / meta-analysis / 2016
Lowering LDL-C via statins and nonstatin therapies upregulating LDL receptors is associated with similar reductions in major vascular events.
A meta-regression analysis of 49 trials (312,175 participants) evaluated cardiovascular risk reductions across 9 approaches to lowering LDL-C. The relative risk of major vascular events per 1-mmol/L (38.7-mg/dL) reduction in LDL-C was 0.77 (95% CI, 0.71-0.84) for statins and 0.75 (95% CI, 0.66-0.86) for nonstatin interventions upregulating LDL receptors (diet, bile acid sequestrants, ileal bypass, and ezetimibe; between-group difference P = .72). For these 5 therapies combined, the RR was 0.77 (95% CI, 0.75-0.79). Achieved LDL-C levels were significantly associated with lower rates of major coronary events in both primary (1.5% lower rate per 1-mmol/L reduction) and secondary prevention trials (4.6% lower rate per 1-mmol/L reduction).
- Study type
- Systematic review and meta-regression of RCTs
- Who was studied
- 312,175 participants across 49 randomized clinical trials
- What was measured
- Relative risk of major vascular events per absolute reduction in LDL-C; 5-year rate of major coronary events
THE PAPER
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. JAMA, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.